User:Mr. Ibrahem/Copanlisib

Mr. Ibrahem/Copanlisib
Clinical data
Pronunciation	Aliqopa /ˌælɪˈkoʊpə/ AL-ih-KOH-pah
Trade names	Aliqopa
Other names	BAY 80-6946
AHFS/Drugs.com	Monograph
MedlinePlus	a617044
License data	EU EMA: by INN; US DailyMed: copanlisib; US FDA: 209936;
Routes of; administration	intravenous infusion only
Drug class	PI3-kinase inhibitor
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Protein binding	84.2%
Metabolism	CYP3A4/5 (≈90%), CYP1A1 (≈10%)
Elimination half-life	39.1 hours (range: 14.6 to 82.4)
Excretion	Feces (64%), Urine (22%); 14% were not recovered
Identifiers
	IUPAC name 2-Amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide;
Chemical and physical data
Formula	C23H28N8O4
Molar mass	480.529 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=C(C=CC2=C1N=C(N3C2=NCC3)NC(=O)C4=CN=C(N=C4)N)OCCCN5CCOCC5;
	InChI InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14H,2,5-12H2,1H3,(H2,24,26,27)(H,28,29,32); Key:PZBCKZWLPGJMAO-UHFFFAOYSA-N;

Copanlisib, sold under the brand name Aliqopa, is a medication used to treat follicular lymphoma.^[3] It is used in those who have failed other treatments.^[3] It is given by injection into a vein.^[3]

Common side effects include high blood sugar, diarrhea, weakness, high blood pressure, low white blood cells, nausea, pneumonia, and low platelets.^[3] Other side effects may include infection and pneumonitis.^[3] Use in pregnancy may harm the baby.^[3] It is a PI3-kinase inhibitor.^[1]

Copanlisib was approved for medical use in the United States in 2017.^[3] As of 2022 it is not approved in either the United Kingdom or Europe.^[4] In the United States it costs about 5,000 USD per dose as of 2022.^[5]

References[edit]

^ ^a ^b "Copanlisib Monograph for Professionals". Drugs.com. Retrieved 7 January 2022.
^ ^a ^b ^c ^d "FDA Prescribing information for Aliqopa" (PDF). Archived (PDF) from the original on 2021-04-06. Retrieved 2021-05-25.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ "DailyMed - ALIQOPA- copanlisib injection, powder, lyophilized, for solution". dailymed.nlm.nih.gov. Archived from the original on 18 March 2021. Retrieved 7 January 2022.
^ "Copanlisib". SPS - Specialist Pharmacy Service. 30 December 2015. Archived from the original on 3 October 2021. Retrieved 7 January 2022.
^ "Aliqopa Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 2019-04-12. Retrieved 2022-01-07.

[AHFS2022-1] "Copanlisib Monograph for Professionals". Drugs.com. Retrieved 7 January 2022.

[AliPI-2] "FDA Prescribing information for Aliqopa" (PDF). Archived (PDF) from the original on 2021-04-06. Retrieved 2021-05-25.

[PI2022-3] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ "DailyMed - ALIQOPA- copanlisib injection, powder, lyophilized, for solution". dailymed.nlm.nih.gov. Archived from the original on 18 March 2021. Retrieved 7 January 2022.

[SP2022-4] "Copanlisib". SPS - Specialist Pharmacy Service. 30 December 2015. Archived from the original on 3 October 2021. Retrieved 7 January 2022.

[5] "Aliqopa Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 2019-04-12. Retrieved 2022-01-07.

[1]

[2]

[3]

[4]

[5]